open access
First trimester screening and progesterone levels in HIV positive women under HAART therapy
Affiliations- Women Clinical Hospital, IASI, Romania
- Department of Obstetrics and Gynecology, “Grigore T Popa” University of Medicine and Pharmacy, IASI, Romania
open access
Abstract
Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease. Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy.
Material and methods: It was a prospective study that took place between January 2017- December 2019 in ʺCuza-Vodăʺ Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women.
Results: Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy.
Discussion: These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome.
Conclusions: Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.
Abstract
Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease. Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy.
Material and methods: It was a prospective study that took place between January 2017- December 2019 in ʺCuza-Vodăʺ Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women.
Results: Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy.
Discussion: These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome.
Conclusions: Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.
Keywords
HIV; AIDS; pregnancy; antiretroviral therapy
About this articleTitle
First trimester screening and progesterone levels in HIV positive women under HAART therapy
Journal
Issue
Article type
Research paper
Pages
224-228
Published online
2021-04-26
Page views
5609
Article views/downloads
771
DOI
Pubmed
Bibliographic record
Ginekol Pol 2022;93(3):224-228.
Keywords
HIV
AIDS
pregnancy
antiretroviral therapy
Authors
Ursache Alexandra Iasi
Tibeica Maria Alexandra
Onofriescu Mircea
Luca Alexandru
Matasariu Daniela Roxana
Nemescu Dragos
References (16)- Dorobăţ CM, Haliciu AM, Bejan C. Interdisciplinary correlations regarding the clinical and paraclinical evaluations in HIV-positive pregnant women. Rev Med Chir Soc Med Nat Iasi. 2014; 118(3): 749–752.
- Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1(1): a006841.
- Smith JH, Whiteside A. The history of AIDS exceptionalism. J Int AIDS Soc. 2010; 13: 47.
- Wainberg MA, Jeang KT. 25 years of HIV-1 research — progress and perspectives. BMC Med. 2008; 6: 31.
- Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 2007; 37(Suppl 1): S94–S102.
- Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014; 28(3): 371–402.
- Fanales-Belasio E, Raimondo M, Suligoi B, et al. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita. 2010; 46(1): 5–14.
- Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS treatments: future trends. Infect Disord Drug Targets. 2018; 18(1): 15–22.
- Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015; 211(1): 10–18.
- Price JT, Phiri WM, Freeman BL, et al. Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: a feasibility study. PLoS One. 2020; 15(1): e0224874.
- Price JT, Vwalika B, Freeman BL, et al. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial. BMC Pregnancy Childbirth. 2019; 19(1): 81.
- Papp E, Balogun K, Banko N, et al. Low prolactin and high 20-α-hydroxysteroid dehydrogenase levels contribute to lower progesterone levels in hiv-infected pregnant women exposed to protease inhibitor-based combination antiretroviral therapy. J Infect Dis. 2016; 213(10): 1532–1540.
- Musyoki SK, Chelimo K, Mining SK, et al. The trends of progesterone hormone in advancing pregnancy of Human Immunodeficiency Virus-infected women: a cohort study in western Kenya. IJSTR. 2015; 3(7): 6698–6706.
- LaVigne KA, Seligman NS, Berghella V. Offering aneuploidy screening to HIV-positive women: routine counselling or not? BJOG. 2011; 118(7): 775–778.
- Patil M, Panchanadikar TM, Wagh G. Variation of papp-a level in the first trimester of pregnancy and its clinical outcome. J Obstet Gynaecol India. 2014; 64(2): 116–119.
- Chougrani I, Muller F, Marcelin L, et al. Combined first-trimester Down syndrome screening in HIV-infected women. Eur J Obstet Gynecol Reprod Biol. 2016; 203: 274–278.
